MDMA-Assisted Psychotherapy for PTSD

This is a pilot Phase 1/Phase 2 open-label study exploring Cognitive-Behavioral Conjoint Therapy (CBCT) integrated with MDMA-assisted psychotherapy for the treatment of chronic posttraumatic stress disorder (PTSD). This study enrolled 6 dyads (pairs) consisting of one participant diagnosed with PTSD, and one concerned significant other who does not have a current PTSD diagnosis but who is experiencing problems associated with the psychosocial circumstances related to the PTSD participant's diagnosis. The primary outcome measure is the Clinician-Administered PTSD Scale according to DSM-5 (CAPS-5) administered to the participant with PTSD. Additional measures evaluate the qualities of the relationship between the participants, and psychological distress in the significant other.

Read Source: MAPS